ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment

Withdrawn before enrolling · Phase 2

Conditions studied: Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ILX-295501 in treating patients who have stage III or stage IV ovarian cancer that has not responded to previous therapy.

Key facts

Study ID

NCT00005645

Run by

Genzyme, a Sanofi Company

People needed

0

Starts

1999-05-01

Last updated by the study team

2018-09-18

Who can join

Age: 18 and older, up to 120. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Jonsson Comprehensive Cancer Center, UCLA — Los Angeles, California, United States
• Indiana University Cancer Center — Indianapolis, Indiana, United States
• Mercy Medical Center, Inc. — Baltimore, Maryland, United States
• Barnes-Jewish Hospital — St Louis, Missouri, United States
• Billings Oncology Associates — Billings, Montana, United States
• St. Vincents Comprehensive Cancer Center — New York, New York, United States
• Sarah Cannon-Minnie Pearl Cancer Center — Nashville, Tennessee, United States
• Virginia Mason Medical Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.